1. Home
  2. TLSI vs HCVI Comparison

TLSI vs HCVI Comparison

Compare TLSI & HCVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TLSI
  • HCVI
  • Stock Information
  • Founded
  • TLSI 2010
  • HCVI 2021
  • Country
  • TLSI United States
  • HCVI United States
  • Employees
  • TLSI N/A
  • HCVI N/A
  • Industry
  • TLSI Medical Specialities
  • HCVI Blank Checks
  • Sector
  • TLSI Health Care
  • HCVI Finance
  • Exchange
  • TLSI Nasdaq
  • HCVI Nasdaq
  • Market Cap
  • TLSI 166.8M
  • HCVI 176.6M
  • IPO Year
  • TLSI N/A
  • HCVI 2021
  • Fundamental
  • Price
  • TLSI $4.73
  • HCVI $10.66
  • Analyst Decision
  • TLSI Strong Buy
  • HCVI
  • Analyst Count
  • TLSI 2
  • HCVI 0
  • Target Price
  • TLSI $14.00
  • HCVI N/A
  • AVG Volume (30 Days)
  • TLSI 69.8K
  • HCVI 31.1K
  • Earning Date
  • TLSI 08-14-2024
  • HCVI 01-01-0001
  • Dividend Yield
  • TLSI N/A
  • HCVI N/A
  • EPS Growth
  • TLSI N/A
  • HCVI N/A
  • EPS
  • TLSI N/A
  • HCVI N/A
  • Revenue
  • TLSI $24,736,000.00
  • HCVI N/A
  • Revenue This Year
  • TLSI $61.24
  • HCVI N/A
  • Revenue Next Year
  • TLSI $47.32
  • HCVI N/A
  • P/E Ratio
  • TLSI N/A
  • HCVI N/A
  • Revenue Growth
  • TLSI 67.75
  • HCVI N/A
  • 52 Week Low
  • TLSI $3.32
  • HCVI $10.30
  • 52 Week High
  • TLSI $10.42
  • HCVI $11.47
  • Technical
  • Relative Strength Index (RSI)
  • TLSI 36.52
  • HCVI 60.14
  • Support Level
  • TLSI $4.80
  • HCVI $10.62
  • Resistance Level
  • TLSI $5.32
  • HCVI $10.66
  • Average True Range (ATR)
  • TLSI 0.34
  • HCVI 0.01
  • MACD
  • TLSI -0.02
  • HCVI 0.00
  • Stochastic Oscillator
  • TLSI 3.06
  • HCVI 100.00

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

About HCVI Hennessy Capital Investment Corp. VI

Hennessy Capital Investment Corp VI is a shell company.

Share on Social Networks: